

Public FAQ

1. What is changing in the management of obesity?

People in England over the age of 18 living with obesity and weight-related health issues, will be able to access the weight loss drug Tirzepatide (Mounjaro®).

Tirzepatide is currently prescribed for the treatment of type 2 diabetes mellitus but will now also be available for weight loss purposes.

2. Can I access Tirzepatide straight away through the NHS?

This is unlikely. We are following a nationally developed staged approach is being used to help cope with the huge demand this will place on existing healthcare services. This allows the prescribing of Tirzepatide and the appropriate support for patients to be set up in a safe way. This staged approach is also being followed in Cheshire and Merseyside.

Tirzepatide will initially be offered to individuals facing the most significant health risks related to their weight.

At present you CAN NOT gain access to Tirzepatide (or other weight loss drugs) directly from your GP. In line with the rest of England we are making access to Tirzepatide available in community/primary care settings this summer to those eligible under the [NHS England Commissioning Guidance](#).

Please keep monitoring this website as we will update it when your local service is open to referrals. Your GP can not refer you for access to tirzepatide before this.

3. Who is eligible for access to Tirzepatide (Mounjaro®) for weight loss?

The National Institute of Health and Care Excellence (NICE) published recommendations for tirzepatide but recognised the need for a gradual approach to prioritise treatment for patients. So, NHS England developed qualifying criteria and patient groups who should be able to access tirzepatide first.

To be able to access the drug in the first 3 years, patients must meet the criteria we have outlined below.

Are you eligible for Tirzepatide through the NHS to support weight loss?

Cohort 1 - will start from 23 June 2025 with services opening in Cheshire and

At least 4 of the 5 health conditions listed below plus a BMI of at least 40*.

Merseyside during this summer.	
Cohort 2 – will start from 23 June 2026.	<p>In addition to the patients in Cohort 1, access to the drug will also be offered to patients meeting the following criteria for year 2.</p> <p>At least 4 of the 5 health conditions listed below plus a BMI of 35 to 39.9*.</p>
Cohort 3 – will start from 1st April 2027	<p>In addition to patients in Cohorts 1 and 2, access to the drug will also be offered to patients meeting the following criteria for year 3.</p> <p>At least 3 of the 5 health conditions plus a BMI of at least 40*.</p>
<p>Eligible conditions in cohorts 1-3 (see above).</p> <ul style="list-style-type: none"> 6. type 2 diabetes mellitus 7. high blood pressure (hypertension) 8. heart disease (cardiovascular disease) 9. obstructive sleep apnoea 10. abnormal blood fats (dyslipidaemia) 	
<p><i>*Due to an increased risk of health conditions at lower BMI thresholds in these populations, the BMI applied to assess eligibility for Tirzepatide must be adjusted by 2.5 kg/m² in people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds to ensure equitable clinical prioritisation and access to appropriate treatment.</i></p>	

NICE has committed to reviewing access criteria after year 3 to evaluate the implementation and delivery of Tirzepatide.

Further details on the prioritisation of availability of Tirzepatide can be found in the [NHS England Interim Commissioning Guidance for Tirzepatide](#).

4. I meet the eligibility criteria above; how can I be prescribed Tirzepatide for weight loss?

Please keep an eye on this website as we are in the process of establishing new community weight loss prescribing services, these will be in place in the next couple of months. Please don't contact your GP before this date, as they won't be able to help yet.

If you don't meet the new NHS rules, you won't be able to get Tirzepatide through the NHS.

5. Can my GP, or the community weight management prescribing service, prescribe the other GLP1 weight loss drugs to me (Liraglutide – Saxenda or Semaglutide – Wegovy)?

NICE has not approved these drugs for prescribing in GP/Community Settings so they are not available in our community weight loss prescribing service.

6. How does Tirzepatide work?

The weight loss medicine tirzepatide also known as Mounjaro® is a GLP-1/GIP agonist. Other medications such as semaglutide (Wegovy®), liraglutide (Saxenda®), are known as GLP-1 agonists. They mimic gut hormones released by the body after eating, telling the brain you are full, they also slow down the time it takes the stomach to empty and help control blood sugar levels.

Until now most of these medicines have been used in the NHS to treat diabetes, to help control blood sugar levels helping improve diabetes and other health conditions.

Tirzepatide (Mounjaro®) can only be prescribed by a healthcare professional alongside programmes that support people to lose weight and live healthier lives, by making changes to their diet and physical activity. Tirzepatide (Mounjaro®) is an injection, that you inject yourself once a week.

More information can be found here: [GLP-1 medicines for weight loss and diabetes: what you need to know - GOV.UK](#)

7.1 Which services are available to support me to lose weight without being prescribed a GLP1 weight loss drug?

Tirzepatide might not be suitable for everyone and not everyone who meets the eligibility criteria will want to use it to support their weight loss. There are other options available including weight loss programmes that use tried and tested methods such as lifestyle and behavioural changes, nutrition and physical activity advice. Please speak to a healthcare professional about the best option for you in your local area.

There are a [range of local weight management services which offer support in losing weight](#). These will vary depending on where you live. These include services commissioned by our local authorities.

The [NHS Digital Weight Management Programme](#) supports adults living with obesity who also have a diagnosis of diabetes, hypertension or both, to manage their weight and improve their health. It is a 12-week online behavioural and lifestyle programme that people can access via a smartphone or computer with internet access.

More information about obesity treatment is available [via the NHS website](#).

The [NHS Type 2 Diabetes Path to Remission Programme](#) is available if you are aged 18 to 65, have a diagnosis of type 2 diabetes within the last 6 years and have a

BMI over 27 kg/m² (for people from White ethnic groups) or over 25 kg/m² (for people from Black, Asian and other ethnic groups).

Adults can access the [NHS Diabetes Prevention Programme](#) if they have had a blood test in the last year that shows they are at risk of diabetes.

There are also a range of NHS online tools you can access.

[Lose weight - Better Health - NHS](#)

[How to be more active - Better Health - NHS](#)

[NHS Food Scanner app](#)

We also know there will be many people who do not qualify for weight loss medications which may cause disappointment and/or exacerbate new and existing mental health and wellbeing issues. People may find [NHS talking therapies](#) a helpful source of support.

7.2 I am eligible for tirzepatide to help me with weight loss: Which service Services will provide me with support?

For people meeting the eligibility criteria described in section 3 NHS commissioned community based weight loss prescribing services can support you in prescribing Tirzepatide. You will also receive support in relation to your lifestyle alongside the medication.

Every patient prescribed Tirzepatide on the NHS is required to participate in a specifically designed 'wrap-around' care service, as stipulated under NICE guidance. This focuses on diet, nutrition and increasing physical activity. Patients cannot be prescribed Tirzepatide if they do not wish to get the wrap-around care support.

When you are prescribed Tirzepatide the person making the prescription will refer you to this service (provided by Reed Health who also locally provide the Diabetes Prevention Programme) who provide this support in Cheshire and Merseyside.

If you do not engage with this “wrap around” support you may have your prescription of Tirzepatide stopped.

You can also be referred to a specialist weight management services can support you who can support people with more complex support needs and prescribe medications if you meet the eligibility criteria in section 3.

7.3 Can I be referred under Right to Choose to a digital only weight loss provider such as Oviva?

At present there are no “Right to Choose” providers, including Oviva, that meet our [local commissioning policy](#) and as a result you **CAN NOT** be referred under right to choose. If a provider becomes eligible, we will update this web page.

8. What are side effects of the medication?

Like all medications, Tirzepatide can have side effects, and healthcare professionals should discuss these with you. The medication comes with a patient information leaflet listing common side effects including:

- feeling sick
- indigestion
- constipation
- diarrhoea.

There can be some more serious side effects, such as low blood sugar, gallstones and inflammation of the pancreas (pancreatitis).

Tirzepatide is a new medication and any side effects should be reported through the [Yellow Card Scheme](#), the government's system for tracking medicine-related side effects.

9. How long can or should I take it for?

NICE guidance recommends that, if you do not lose enough weight (5%) after 6 months of being on the highest dose you can manage, Tirzepatide should be stopped. This is because the medication is not working as well as it should be for you.

Currently, there is no specified time limit for Tirzepatide prescriptions. The decision to continue or stop Tirzepatide should be discussed with an appropriate healthcare professional.

10. Can I take it if I'm pregnant or trying to get pregnant?

If you are trying to get pregnant, you should have a discussion with an appropriate healthcare professional. There are specific recommendations about when to stop the medication before trying to get pregnant. Tirzepatide is not recommended in pregnancy or during breastfeeding because we have limited safety data. It should be stopped if you become pregnant.

The Faculty for Sexual and Reproductive Health has produced a patient information leaflet about how these medications affect contraception like the pill.

11. What if I am already using Tirzepatide?

Patients can continue taking Tirzepatide if they are prescribed it by the NHS to manage their diabetes. If you have any questions, contact a suitable healthcare professional.

If patients are using Tirzepatide bought privately, they may be able to access the medication through an NHS prescription if they meet the NHS qualifying criteria outlined in section 3. However, patients should not gain advantage over other

patients waiting for NHS care. You will also be expected to engage with the wrap around support that is mandated alongside tirzepatide for weight loss.

It is important that your GP is aware you are taking Tirzepatide even if it hasn't been prescribed by the NHS. It may affect your health and interact with other treatments.

12. I am currently on a waiting list for NHS specialist weight management services. Can I transfer to another list to access this drug?

A healthcare professional will advise you if you are eligible and if it is clinically appropriate for you to receive Tirzepatide as part of your care. This will reflect the criteria in section 3.

13. Will I be supported while taking the medication?

Every patient prescribed Tirzepatide on the NHS is required to participate in a specifically designed 'wrap-around' care service, as stipulated under NICE guidance. This focuses on diet, nutrition and increasing physical activity. Patients cannot be prescribed Tirzepatide if they do not wish to get the wrap-around care support.

When you are prescribed Tirzepatide the person making the prescription will refer you to this service (provided by Reed Health who also locally provide the Diabetes Prevention Programme) who provide this support in Cheshire and Merseyside.

If you do not engage with this "wrap around" support you may have your prescription of Tirzepatide stopped.

14. What is Wraparound Care

Wraparound care is the name given to the support programme that must be provided alongside tirzepatide (Mounjaro®).

This includes:

- Advice on healthy eating and nutrition.
- Support to increase physical activity.
- Help with making long-term lifestyle changes.

You must agree to take part in this support programme in order to be prescribed tirzepatide for weight loss.

15. Will there be a cost to the patient for Tirzepatide prescriptions?

Normal prescription charges will apply unless you are entitled to free NHS prescriptions (for example, because you have a medical exemption certificate).